Somewhere in the second or third year of chasing facial redness, most people arrive at the gut. A practitioner mentions it, or a forum post does, and the logic feels compelling: the skin is inflamed, inflammation comes from somewhere, and a stomach infection is a plausible somewhere. So you get tested, you come back positive, and you take two weeks of triple therapy expecting your face to clear.
Sometimes it helps. Often it does not. Understanding why requires being honest about what the evidence on H. pylori and rosacea actually shows, which is messier and more interesting than either the wellness version or the dismissive version.
Quick answer
H. pylori and rosacea are statistically associated in observational research, with a pooled odds ratio of 1.51 across studies. That association weakens or reverses under stronger study designs. Population studies using prescription records found no association, and a two-sample Mendelian randomisation analysis found no causal relationship at all. Eradication therapy has improved rosacea severity in small randomised work, but the control group improved too, and no study has ever shown that treating H. pylori lowers Demodex density. The practical position is that eradication is worth pursuing if you have gastrointestinal symptoms or an independent indication, and is not a substitute for treating the follicle.
What the evidence actually says about H. pylori and rosacea
This question has been studied for three decades and the answer keeps depending on how you ask it.
A 2024 meta-analysis pooled the observational literature and found a significantly higher prevalence of infection in people with rosacea, with an odds ratio of 1.51 and a confidence interval running from 1.17 to 1.95. Heterogeneity between the included studies was high at 79 percent, meaning the studies disagreed with each other substantially.
The same meta-analysis then did something most do not, and split the studies by how infection was determined. In population-based studies that identified infection from prescription records for eradication drugs, the odds ratio was 0.90 and the association vanished.
A 2025 two-sample Mendelian randomisation study went further. This design uses inherited genetic variants as a natural randomisation, which sidesteps most of the confounding that plagues observational work. It found no causal relationship between H. pylori infection and rosacea, and its authors concluded that routine testing and routine eradication may not benefit rosacea patients.
The pattern is the giveaway. When the effect is biggest in the weakest designs and disappears in the strongest, the usual explanation is confounding rather than causation. People with chronic skin complaints see doctors more, get tested more, and are more likely to have an infection detected that a comparison group also has but never had looked for.
Where it gets less tidy
Two findings keep the story of H. pylori and rosacea from being a clean dismissal.
The first is that eradication trials have shown benefit. In a randomised comparison of 60 rosacea patients positive for the organism, severity scores fell from 9.32 to 2.39 in the eradication group against 9.20 to 5.35 in those receiving standard care alone.
Note what that graph shows honestly. Both groups improved. The eradication group improved more, and the difference was statistically significant, but this was a small study and mite counts were never measured in either arm.
The second is that the association is not uniformly positive. A large Korean population study found an inverse relationship between H. pylori and atopic, skin and autoimmune diseases. A relationship that runs in opposite directions in different populations is not a simple causal chain.
The mechanisms that have been proposed, and what survives scrutiny
Several plausible bridges have been suggested between a stomach infection and a red face.
Systemic inflammatory load
Chronic infection drives circulating inflammatory mediators. Rosacea-prone skin has a lowered threshold for inflammatory response. Adding to the systemic burden could plausibly lower that threshold further. This is the most defensible mechanism, and it is also non-specific: any chronic inflammatory source would do the same, which is precisely why it fails to make this particular organism a special case rather than an ordinary one.
Vasoactive mediators
Infection has been linked to nitric oxide and other vasoactive compounds that could contribute to flushing. This remains mechanistically plausible and clinically unproven.
The antibiotics themselves
Eradication regimens include antibiotics with independent anti-inflammatory activity in skin. When someone improves after triple therapy, separating the effect of clearing the organism from the effect of two weeks of systemic antibiotics is not possible without a design that controls for it. None of the eradication trials has done this.
What does not survive
There is no evidence that H. pylori affects Demodex mites. No study has shown that eradication reduces mite density. The organism lives in the gastric mucosa. The mite lives in the facial follicle. They do not meet, and no mechanism connecting them has been demonstrated.
This matters because the promise that circulates online is often precisely that: clear the gut and the mites resolve. That claim has no support.
What this means if you are the person with the red face
The practical position that fits the evidence is narrower than the enthusiastic version and broader than the dismissive one.
Test if you have gastrointestinal symptoms. Indigestion, reflux, upper abdominal pain, nausea, bloating or a family history of gastric disease are all independent reasons to test, and treating a confirmed infection is worthwhile on its own terms regardless of your skin.
Do not test the gut instead of examining the skin. This is the most common sequencing error we see. Months disappear into gut protocols while the follicle goes unexamined and untreated, and the mite population continues to build. If facial redness is your complaint, the face needs looking at first.
If you test positive and treat, judge the result honestly. Give it eight to twelve weeks and assess whether flushing frequency and background redness changed. If they did, that is useful information. If nothing changed, the infection was probably incidental, which is common.
Do not take eradication therapy speculatively. Triple and quadruple regimens are substantial courses of antibiotics with real effects on the wider microbiome and a real contribution to antibiotic resistance. Taking them without a confirmed infection is not a low-cost experiment, and the resistance picture has worsened enough in the last decade that eradication now often fails on the first attempt even when it is properly indicated.
Be careful about what a positive result means. Roughly half the world’s population carries this organism. A positive test in someone with rosacea is far more likely to be a coincidence than an explanation, simply because the background prevalence is so high. That is the single most useful number to hold on to when someone tells you your face is a stomach problem.
Treat the follicle either way. Whatever the gut situation, if mite density is driving your skin then a topical acaricidal step is what lowers it. Our clinical evidence review, the guide to tea tree oil and the review of permethrin cover the options. For redness specifically, azelaic acid and metronidazole act on inflammation without acting on mites, which is a distinction worth understanding before you choose.
Where the gut genuinely does matter
Rejecting an overstated claim is not the same as rejecting the gut entirely, and it would be a mistake to read this article that way.
The best-evidenced gut link in rosacea is not H. pylori but small intestinal bacterial overgrowth, where a controlled study found it in 52 of 113 rosacea patients against 3 of 60 controls, and where treatment cleared skin lesions in the majority of those treated. Diet also has a defensible role, not by starving mites but by modulating the sebum supply that feeds both mites and Malassezia yeast, which is covered in our Demodex diet guide. The broader picture is set out in our pillar on Demodex and gut health, and the evidence for oral supplements is tiered honestly in supplements for Demodex.
The distinction worth holding is between internal factors that plausibly modulate the terrain and internal factors claimed to remove the organism. The first is reasonable. The second is not supported for H. pylori.
For practitioners
The divergence between observational and Mendelian randomisation results here is the most instructive feature of this literature and worth explaining to patients directly, because it models how to weigh evidence rather than simply issuing a verdict.
Three specific confounders plausibly generate the observational signal. Detection bias, since rosacea patients have higher healthcare contact and therefore higher rates of incidental testing. Socioeconomic and geographic clustering, since H. pylori prevalence varies enormously by region and birth cohort while rosacea ascertainment varies with dermatology access. And reverse indication, since many rosacea patients have already had prolonged tetracycline exposure, which alters gastric colonisation and confounds prescription-record definitions in both directions.
Clinically, the reasonable position is to test on gastrointestinal indication rather than dermatological indication, treat confirmed infection on its own merits, and avoid framing eradication as antiparasitic therapy. Where a patient has already had eradication and reports skin improvement, the antibiotic effect is a live alternative explanation worth naming rather than attributing the change to clearance of the organism. Related material sits in our Demodex and rosacea clinical guide and the research section.
Frequently asked questions
Does H. pylori cause rosacea?
On current evidence, no. The link between H. pylori and rosacea is an association rather than a cause. Observational studies find an association, but population-scale and genetic causal analyses do not support causation. Association in this literature most likely reflects shared risk factors and detection bias.
Will treating H. pylori clear my Demodex mites?
No. No study has shown any effect of eradication therapy on mite density, and there is no plausible mechanism by which a gastric organism would affect a facial follicular mite.
Should I get tested for H. pylori if I have rosacea?
If you have digestive symptoms, yes, and for their own sake. If your only symptom is facial redness, the evidence does not support routine testing, and the 2025 causal analysis explicitly concluded as much.
My face improved after triple therapy. What happened?
Several possibilities, and you cannot distinguish them from a single personal result. The infection may have been contributing. The antibiotics may have acted on skin inflammation directly. Rosacea also fluctuates naturally, which is why the control group in the eradication trial improved without eradication.
What about SIBO, leaky gut and parasites?
SIBO has better rosacea evidence than H. pylori does. Intestinal permeability is mechanistically interesting and clinically hard to measure reliably. Intestinal parasites are a separate question from Demodex, which is not an intestinal organism. See our gut health pillar for the fuller picture.
Is it worth doing a gut protocol before treating my skin?
We would not sequence it that way. Skin assessment and mite-directed treatment can run alongside gut work. Delaying the skin plan while the mite population builds is the most costly version of this decision.
Where to go next
Start with the Demodex quiz if you have not established whether mites are part of your picture. If your redness came with rough texture, see Demodex and rough skin texture. If your skin worsened after a steroid cream, see steroid-induced Demodex. If your rosacea keeps returning after successful treatment, read why rosacea keeps coming back.
References
- Gao Y, Yang XJ, Zhu Y, Yang M, Gu F. Association between rosacea and Helicobacter pylori infection: a meta-analysis. PLOS ONE. 2024;19(4):e0301703. PubMed
- No causal relationship between Helicobacter pylori infection and rosacea: a two-sample Mendelian randomization study. Clinical, Cosmetic and Investigational Dermatology. 2025. Full text
- Aghaei M, Aghaei S, Behshadnia F, et al. Association between the treatment of rosacea and eradication of Helicobacter pylori infection. Advanced Biomedical Research. 2023;12:173.
- Jorgensen AR, Egeberg A, Gideonsson R, Weinstock LB, Thyssen EP, Thyssen JP. Rosacea is associated with Helicobacter pylori: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2017;31(12):2010-2015.
- Saleh P, Naghavi-Behzad M, Herizchi H, Mokhtari F, Mirza-Aghazadeh-Attari M, Piri R. Effects of Helicobacter pylori treatment on rosacea: a single-arm clinical trial study. Journal of Dermatology. 2017;44(9):1033-1037.
- Cho SI, Lee H, Yang MS, Cho SJ, Lee DH. Inverse association between Helicobacter pylori infection and atopic, skin, and autoimmune diseases: a nationwide population-based study in South Korea. Allergy. 2021;76(12):3824-3826.
- Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clinical Gastroenterology and Hepatology. 2008;6(7):759-764.
- Dakovic Z, Vesic S, Vukovic J, Milenkovic S, Jankovic-Terzic K, Dukic S. Ocular rosacea and treatment of symptomatic Helicobacter pylori infection: a case series. Acta Dermatovenerologica Alpina, Pannonica et Adriatica. 2007;16(2):83-86.
- Omarov N, Gezdur O. Exploring the potential link between Helicobacter pylori and rosacea: a retrospective matched cohort study. Medical Science and Discovery. 2025;12(6):207-212.
- Barakji YA, Ronnstad ATM, Christensen MO, et al. Assessment of frequency of rosacea subtypes in patients with rosacea: a systematic review and meta-analysis. JAMA Dermatology. 2022;158(6):617-625.
- Wedi B, Kapp A. Helicobacter pylori infection in skin diseases: a critical appraisal. American Journal of Clinical Dermatology. 2002;3(4):273-282.
About the author. Marina Ivakhnenko is a functional skin
practitioner who works with Demodex-related skin and eyelid conditions. This
article is educational and is not a substitute for individual medical care.
Do not start, stop or change a prescribed medicine on the basis of anything
you read here. If you are using a topical steroid on your face, speak to the
prescriber before altering how you use it.